Coronavirus (2019-nCoV) outbreak is still one of the major concern amongst scientific community. Different observational studies were undertaken to identify the possible risk factors for Covid 19 infection and related poor outcomes in that Hypertension was found to be independently associated with the severity of COVID-19 patient admission & Hypertension is a risk factor for aggravation of the disease in COVID-19 patients. The new data, published in JAMA Network Open, shows that after adjusting for multiple variables, COVID-19 patients treated with ACE inhibitors and ARBs had a significantly lower risk of death and severe adverse events. BRACE CORONA trial, presented at the ESC Congress, showed that hospitalized patients with COVID-19 who continued on their previously prescribed ACE inhibitors and ARBs were not at an increased risk of dying or remaining in the hospital when compared to patients who stopped the medication. The REPLACE COVID trial, which was published came to a similar conclusion. Listen to the expert to know more on ARB Usage in COVID-19.
